Literature DB >> 6120717

Hypnotic activity and effects on performance of lormetazepam and camazepam--analogues of temazepam.

A N Nicholson, B M Stone.   

Abstract

1 The effects of lormetazepam and camazepam on sleep electroencephalography, visuo-motor coordination, digit symbol substitution and subjective assessments of mood and sleep quality were compared with placebo in six young adult males (18-27 years). The study was double blind. 2 Over the dose range 0.5, 1.0 and 2.0 mg, lormetazepam increased total sleep time (P less than 0.05), reduced wakefulness (P less than 0.05) and drowsy sleep (linear effect P less than 0.05). With 2.0 mg there were increases in stage 3 (P less than 0.05) and reduction in rapid eye movement sleep (P less than 0.01). Overnight ingestion of 2.0 mg, was followed by impaired visuo-motor coordination and fewer substitutions with the digit symbol test. 3 The hypnotic effect of 10-20 mg camazepam was limited to reduced awake activity (P less than 0.05), and with 20 mg there were increased substitutions on the digit symbol test. After 40 mg overnight stage 4 sleep was reduced (P less than 0.001) and performance at the digit symbol test was impaired (P less than 0.05 at 9.75 h). Morning ingestion of 20 mg camazepam did not alter performance, and the subjects assessed themselves to be more relaxed. 4 Lormetazepam is not specially indicated for those involved in skilled activity, but may prove useful for patients with insomnia resistant to other drugs. Camazepam would appear to be a promising anxiolytic with minimal effects on performance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6120717      PMCID: PMC1402107          DOI: 10.1111/j.1365-2125.1982.tb01398.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  L-tryptophan and sleep in healthy man.

Authors:  A N Nicholson; B M Stone
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1979-11

2.  Diazepam and 3-hydroxydiazepam (temazepam) and sleep of middle age.

Authors:  A N Nicholson; B M Stone
Journal:  Br J Clin Pharmacol       Date:  1979-05       Impact factor: 4.335

3.  Hypnotic activity of 3-hydroxy, N-desmethyldiazepam (oxazepam).

Authors:  A N Nicholson; B M Stone
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

4.  The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C.

Authors:  M Hümpel; V Illi; W Milius; H Wendt; M Kurowski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

  4 in total
  11 in total

1.  Residual effects of lormetazepam on mood and performance in healthy elderly volunteers.

Authors:  J B Deijen; M L Heemstra; J F Orlebeke
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Dose level effects of triazolam on sleep and response to a smoke detector alarm.

Authors:  L C Johnson; C L Spinweber; S C Webb; A G Muzet
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Hypnotic activity of lormetazepam and camazepam.

Authors:  I Oswald
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

4.  Effects of a mu-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in man.

Authors:  C M Bradley; A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

5.  Ascorbic acid and performance in man.

Authors:  P A Pascoe; B M Stone
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Pharmacodynamic correlates of modified absorption: studies with lormetazepam.

Authors:  D M Pierce; R A Franklin; T V Harry; A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

7.  The H1-antagonist mequitazine: studies on performance and visual function.

Authors:  A N Nicholson; B M Stone
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Studies on the central effects of the H1-antagonist, loratadine.

Authors:  C M Bradley; A N Nicholson
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Repeated dose effects of lormetazepam and flurazepam upon driving performance.

Authors:  K A Brookhuis; E R Volkerts; J F O'Hanlon
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  The effects of lormetazepam on aspects of sleep and early morning performance.

Authors:  Z Subhan; I Hindmarch
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.